ACADEMIA

Keio Univ. Board OKs World’s 1st iPS Cell Clinical Research for Spinal Cord Injuries

November 29, 2018
A board of experts at Keio University gave an official stamp of approval on November 27 for what would be the world’s first clinical research on the transplantation of iPS cell-derived nerve cells in patients who have sustained spinal cord…

To read the full story

Related Article

ACADEMIA

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…